Sponsor:
Exai Bio Inc.
Code:
NCT05833360
Conditions
Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Accepted
Interventions
Exai oncRNA blood test
Brief summary:
Conditions
Cancer
Study ID
NCT05833360
Start date
Jul 14, 2023
Status verified date
Mar, 2025
Completion date
Jul 14, 2030
Anticipated
Primary completion date
Jul 14, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Accepted
Enrollment
2400 participants
Anticipated
Arms
Control Cohort
Cancer Predisposition Cohort
Pre-Malignant Condition Cohort
Cancer Patients Cohort
Interventions
Exai oncRNA blood test
Primary outcome measure
Central contacts
Locations
Exai Bio Inc.
Recruiting
Palo Alto, California, United States, 94303
Contacts
Renown Health
Recruiting
Reno, Nevada, United States, 89502
Contacts
Principal Investigator:
Lee S Schwartzberg, MD
Sponsor
Exai Bio Inc.
Last update posted
Mar 18, 2025
Last verified
Mar, 2025
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Exai Bio Inc. on 2025-03-18.